万维提示：
1、投稿方式：在线投稿。
2、期刊网址：https://www.eymj.org/
3、投稿网址：
http://journal.eymj.org/submission/Login.html
4、官网邮箱：ymj@yuhs.ac（主编）
5、官网电话：82-2-2228-2034（主编）
6、期刊刊期：月刊，每月1日出版。
2021年7月6日星期二
投稿须知【官网信息】
Information for Contributors
EDITORIAL POLICY:
The Yonsei Medical Journal (YMJ) is a peer-reviewed journal of medicine published in English on the 1st of every month. The goal of the Yonsei Medical Journal (YMJ) is to publish high quality manuscripts dedicated to clinical or basic research. Any authors affiliated with an accredited biomedical institution may submit manuscripts of original articles, review articles, brief communications, case reports, technical reports, and letters to the Editor. Manuscripts are received with the understanding that they are not under simultaneous consideration by any other publications, and that the review process is conducted in a double-blind manner such that the identities of both the reviewers and authors are kept confidential. The Editors reserve the right to make corrections, both literary and technical, to the papers. The agreement of copyright transfer from all authors should be sent after manuscript acceptance. A copyright transfer form is available at the journal homepage.
ETHICS:
<Research Ethics>
All of the manuscripts should be prepared based on strict observation of research and publication ethics guidelines recommended by the Council of Science Editors (http://www.councilscienceeditors.org/), International Committee of Medical Journal Editors (ICMJE, http://www.icmje.org/), World Association of Medical Editors (WAME, http://www.wame.org/), and the Korean Association of Medical Journal Editors (KAMJE, https://www.kamje.or.kr/board/view?b_name=bo_publication&bo_id=7). It is the author’s responsibility to ensure that a patient’s anonymity be carefully protected.
Any study involving human subject or human data must be approved by the Institutional Review Board (IRB) of the author’s affiliated organization. Please refer to the principles embodied in the Declaration of Helsinki (https://www.wma.net/what-we-do/medical-ethics/declaration-of-helsinki/doh-oct2008/). Animal studies should be performed in compliance with relevant guidelines and approved by the IRB. A statement regarding IRB approval should be included in the Materials and Methods section.
<Redundant Publication and Plagiarism>
Redundant publication is defined as “reporting (publishing or attempting to publish) substantially the same work more than once, without attribution of the original source(s).” Characteristics of reports that are substantially similar include the following: (a) “at least one of the authors must be common to all reports (if there are no common authors, it is more likely plagiarism than redundant publication),” (b) “subjects or study populations are the same or overlapped,” (c) “methodology is typically identical or nearly so,” and (d) “results and their interpretation generally vary little, if at all.”
When submitting a manuscript, authors should include a letter informing the editor of any potential overlap with other already published material or material being evaluated for publication, and should also state how the manuscript submitted to YMJ substantially differs from other materials. If all or part of your patient population was previously reported, this should be mentioned in the Methods section, with citation of appropriate reference(s). The YMJ editorial committee subjects all submitted manuscripts to screening through Turnitin (https://www.turnitin.com/) for plagiarism prior to publication.
<Clinical Trials>
Obligation to register
Clinical trial defined as “any research project that prospectively assigns human subjects to intervention and comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome” should be registered to the primary registry to qualify as prior publication. YMJ accepts registration in any of the primary registries are part of the WHO International Clinical Trials Portal (http://www.who.int/ictrp/en/), NIH ClinicalTrials.gov (http://www.clinicaltrials.gov/), ISRCTN Resister (www.ISRCTN.org), or Clinical Research Information Service (CRIS), Korea CDC (http://www.cdc.go.kr/CDC/eng/main.jsp). Clinical trial registration number should be published at the end of the abstract.
<Authorship>
The Yonsei Medical Journal (YMJ) follows the recommendations for authorship proposed by the International Committee of Medical Journal Editors (ICMJE, 2019, http://www.icmje.org). The recommendations are as follows: “Authorship credit should be based on 1) substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND 2) drafting the work or revising it critically for important intellectual content; AND 3) final approval of the version to be published; AND 4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Author contributions will be published with the final article, and they should accurately reflect contributions to the work. The submitting author is responsible for completing this information at submission, and it is expected that all authors would have reviewed, discussed, and agreed to their individual contributions prior to submission of the manuscript for review for publication.
YMJ permits up to two first co-authors and two corresponding authors.
YMJ does not allow authorship correction after publication unless the editorial staff made an obvious mistake. Before publication, authorship can be changed in cases when all authors request the authorship correction.
<Conflicts of Interest>
Any potential conflicts of interest must be disclosed in this section. If there are no potential conflicts of interest, the following statement should be added: “The authors have no potential conflicts of interest to disclose.”
<Description of Participants>
Ensure correct use of the terms “sex” (biological factors) and “gender” (identity, psychosocial, or cultural factors). Also, unless inappropriate, report the sex or gender of study participants, the sex of animals or cells, and describe the methods used to determine sex or gender. If the study involved an exclusive population (in only one sex, for example), authors should justify why, except in obvious cases (e.g., prostate cancer). Authors should also define how they determined race or ethnicity, and justify their relevance.
MANUSCRIPT SUBMISSION:
Authors should submit manuscripts via the online submission system: http://journal.eymj.org/. Acceptance of manuscripts is based on many factors, including the importance, originality, and priority of the research. The Editor-in-Chief and an Associate Editor generally review manuscripts. Then the selected manuscripts are reviewed by at least two external peer reviewers, and when required, a biostatistician. Upon completion of the review, authors will receive notification of the Editor’s decision by e-mail with comments offered by the reviewers. The author(s) can recommend up to 3 candidates to review the manuscript. Revised manuscripts must be submitted within 3 months of the date on the decision letter in order to maintain their original manuscript number.
PREPARATION OF MANUSCRIPT:
Authors should refer to “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” (http://www.icmje.org/). On the cover letter, authors should make a statement about the originality of their work and disclose previous presentations, reports, or publications that contain any material that appears in the manuscript. If there is a similar or supplemental publication, the authors should provide a copy for the Editors' review. Manuscripts should be written in double space throughout.
REVIEW ARTICLE:
Review articles are usually solicited by the Editor-in-Chief. However, unsolicited Reviews will be also considered. Authors should contact the Editor-in-Chief in advance to determine the appropriateness of their Review Articles for publication. Unsolicited Reviews will undergo peer review. An Abstract is required whereas Materials and Methods section and a Results section are not required. The length of Review Articles is limited to 5,000-8,000 words with a maximum of 100 references. Also, there should be no more than 3 authors.
ORIGINAL ARTICLE:
Manuscripts should begin with the title page followed by an abstract; a list of key words; an introduction; materials and methods; results; a discussion; tables and/or illustrations; and references (up to 40 references).
Title Page: The title page should contain the following information: (1) title (less than 150 characters, including spaces); (2) author list (first name, middle name, and last name); (3) name of the institutions at which the work was performed as well as their positions within the listed institutions; (4) acknowledgement of research support; (5) name, academic degree, address, telephone, fax number, and e-mail address of the corresponding author; (6) running title (less than 50 characters, including spaces); (7) a list of where and when the study has been presented in part elsewhere; (8) ORCID iDs for all authors (Please refer to https://orcid.org/); (9) author contributions. Up to two first co-authors and two corresponding authors are permitted.
Abstract: Abstract must be organized and formatted according to the following headings: (1) Purpose; (2) Materials and Methods; (3) Results; and (4) Conclusion. A trade name may not be used in the title or abstract. The Abstract length is typically 250 words.
Key Words: List 3-6 key words from the list provided in Index Medicus under “Medical Subject Heading (MeSH).”
Text: The text of manuscripts must have the following sections: (1) Introduction; (2) Materials and Methods; (3) Results; and (4) Discussion. The body of the manuscript should be written as concisely as possible. All pages of the manuscript should be numbered. (1) Introduction: This should provide a context or background for the study and states the specific purpose or research objective of or hypothesis tested by the study. This may include mention of papers most closely related to the article, and of the problem. (2) Materials and Methods: Explanation of the experimental methods should be concise but sufficient to allow other workers to reproduce the results. This provides the technical information, apparatus (the manufacturer’s name and brief address) and procedures. Give references and brief descriptions for the methods that have been published. Describe statistical methods with enough detail to enable a reader with access to the original data to verify the reported results. Define statistical terms, abbreviations, and most symbols. (3) Results: This should include a concise textual description of the data presented in tables and figures. (4) Discussion: This section includes the new and important aspects of the study and the conclusions. The data should be interpreted concisely. Speculation is permitted, but it must be supported by the data presented by the authors.
References: References should be numbered consecutively in the order in which they are first mentioned in the text, with numbers as unparenthesized superscripts after any closing punctuation. They should be listed on a separate document under the heading “REFERENCES,” and double-spaced. Reference format should conform to NLM Style Guide (https://www.ncbi.nlm.nih.gov/books/NBK7256/). Titles of journals should be abbreviated according to the Index Medicus style.
When referencing from an abstract, editorial, or published letter, it must be identified as such in parentheses at the end of the reference. When a reference is a personal communication, it should be included in parentheses in the body of the text, and not cited in the reference list.
Reference Style:
Journal articles: List all authors when six or less; when seven or more, list the first six and add et al.
Vega KJ, Pina I, Krevsky B. Heart transplantation is associated with an increased risk for pancreatobiliary disease. Ann Intern Med 1996;124:980-3.
Book: Ringsven MK, Bond D. Gerontology and leader-ship skills for nurse. 2nd ed. Albany (NY): Delmar Publishers; 1996.
Book chapter: Phillips SJ, Whisnant JP. Hypertension and stroke. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis, and management. 2nd ed. New York: Raven Press; 1995. p.465-78.
Tables: Tables should fit within a single page. The Table’s legend may include any pertinent notes and must include definitions of all abbreviations and acronyms that have been used in the Table. For footnotes, the following symbols should be used in this sequence: *, †, ‡, §, ∥, ¶, **, ††, ‡‡, etc. Authors are obligated to indicate the significance of their observations by appropriate statistical analysis.
Illustrations: Figures must be cited consecutively using Arabic numerals. The recommended fonts within the figures are Helvetica or Arial. Figures which are drawn or photographed professionally should be sent as JPG (JPEG) or TIFF files. Authors should review the images of such files on a computer screen to be sure they meet their own quality standard. The complete expense of reproducing color photographs will be charged to the author.
Legends for Tables and Illustrations: Typed legends that use double-spacing should start on a separate page with Arabic numerals corresponding to the Tables or Illustrations. When symbols, arrows, numbers, or letters are used to identify parts of the Tables or Illustrations, they should be individually identified and explained clearly in the legend.
Abbreviations: Authors should limit the use of abbreviations to an absolute minimum. Abbreviations are not to be used in titles. Abstracts may contain abbreviations for terms mentioned many times in the abstract section, but each term must be identified the first time it is mentioned.
Unit of Measurement: Measurements of length, height, weight, and volume should be reported in metric units (meter, kilogram, or liter) or their decimal multiples. Temperature should be in degrees Celsius. Authors must consult the information for authors for the particular journal and should report laboratory information in both the local and International System of Units (SI).
EDITORIAL, PERSPECTIVES, BRIEF COMMUNICATION, COHORT PROFILE, CASE REPORT, TECHNICAL REPORT, LETTER TO THE EDITOR
EDITORIAL, PERSPECTIVES, and BRIEF COMMUNICATION should not exceed 2,000 words excluding the Abstract, References, and Figure/Table legends. No subdivisions such as the Introduction, Materials and Methods, Results, and Discussion are required. COHORT PROFILE should not exceed 2,000 words, excluding the Abstract, References, and Figure/Table legends. No subdivisions, such as the Introduction, Materials and Methods, Results, and Discussion, are required. These articles should describe the rationale for a cohort’s creation, its methods, baseline data, future plans, and key findings. CASE REPORT should consist of an Abstract, Key words, Introduction, Case Report, Discussion and References (no more than 20). The manuscript should have no more than six authors, and no more than three total tables or figures. In addition, the total word count should not exceed 1,000 words excluding the Abstract, References, and Figure/Table legends. The informed consent for publication of clinical data should be obtained from the patients. TECHNICAL REPORT should not exceed 2,000 words excluding the Abstract, References, and Figure/Table legends with up to 20 references. The abstract should be less than 250 words. It is not necessary to have a fully structured abstract for brief communications, case reports, and technical reports. LETTER TO THE EDITOR should have no more than five authors, include no more than one total table or figure, and should not exceed 750 words.
REPORTING GUIDELINES
The guidelines listed below should be followed where appropriate. Please use these guidelines to structure your article.
CONSORT Statement For reporting randomised controlled trials: please use the appropriate extension to the CONSORT statement, including the extension for writing abstracts. SRQR For reporting qualitative research. STARD For reporting diagnostic accuracy studies. STROBE For reporting observational studies in epidemiology. PRISMA For reporting systematic reviews. PRISMA-P For reporting systematic reviews and meta-analysis protocols. PRISMA-ScR For reporting scoping reviews. MOOSE For reporting meta-analyses of observational studies. SPIRIT For reporting protocols for RCTs. STREGA For reporting gene-disease association studies. TRIPOD For reporting studies developing, validating, or updating a prediction model, whether for diagnostic or prognostic purposes. CHEERS For reporting health economic evaluations.
PERMISSION: If any portion of a manuscript has been previously published, the original source must be acknowledged, and the written permission from the copyright holder to reproduce the material must be submitted.
REPRINTS: The reprint order form must be returned along with the corrected galley proofs. Purchased reprints are normally shipped 3 weeks after publication of the journal.
ARTICLE PROCESSING CHARGES: Article processing charges are required for publication in YMJ. An invoice for article processing will be sent to the corresponding author before publication. Your prompt payment of the article processing charges will allow your manuscript to be published quickly and efficiently.
Original articles and unsolicited Review articles: KRW600,000 (USD550) per 6 printed pages or less. Invited review articles are exempt from article processing charges.
Case reports, Brief communications, Technical reports, and Letters to the Editor: KRW350,000 (USD300) per 4 printed pages or less.
Additional pages: KRW120,000 (USD100) per page.
All correspondences, business communications and manuscripts should be mailed to:
Changsoo Kim, M.D., Ph.D., Editor-in-Chief
Yonsei Medical Journal
Yonsei University College of Medicine
50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea
Office Tel: 82-2-2228-2034, Fax: 82-2-2227-8306
E-mail: ymj@yuhs.ac
